Reata Pharma
(RETA)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -73,842 | -297,386 | -212,001 | -140,155 | -67,455 |
| Depreciation Amortization | 308 | 7,766 | 6,202 | 4,048 | 1,988 |
| Accounts payable and accrued liabilities | -4,525 | 8,713 | -3,117 | 3,550 | 3,629 |
| Other Working Capital | -9,966 | -49,575 | 17,138 | 15,219 | -5,148 |
| Other Operating Activity | 29,840 | 94,781 | 79,009 | 46,727 | 21,975 |
| Operating Cash Flow | $-58,185 | $-235,701 | $-112,769 | $-70,611 | $-45,011 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -288 | -1,329 | -1,136 | -462 | -193 |
| Investing Cash Flow | $-288 | $-1,329 | $-1,136 | $-462 | $-193 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 194 | 9,138 | 8,967 | 8,630 | 4,678 |
| Financing Cash Flow | $194 | $9,138 | $8,967 | $8,630 | $4,678 |
| Beginning Cash Position | 590,258 | 818,150 | 818,150 | 818,150 | 818,150 |
| End Cash Position | 531,979 | 590,258 | 713,212 | 755,707 | 777,624 |
| Net Cash Flow | $-58,279 | $-227,892 | $-104,938 | $-62,443 | $-40,526 |
| Free Cash Flow | |||||
| Operating Cash Flow | -58,185 | -235,701 | -112,769 | -70,611 | -45,011 |
| Capital Expenditure | -288 | -1,329 | -1,136 | -462 | -193 |
| Free Cash Flow | -58,473 | -237,030 | -113,905 | -71,073 | -45,204 |